Human C1 inhibitor (hC1INH) is a therapeutic N, O-glycoprotein with a growing number of clinical applications, but the current natural supplies are not likely to meet the clinical demands. Therefore, recombinant approaches are of interest, whereby specific attention has to be paid to the generated glycosylation patterns. Here, the N,O-glycoprotein was expressed in the mammary gland of transgenic rabbits and subjected to glycan analysis. After release of the N-glycans of recombinant-rabbit human C1 inhibitor (rhC1INH) by peptide-N 4 -(N-acetyl-b-glucosaminyl)asparagine amidase F, the oligosaccharides were separated from the O-glycoprotein by centrifugal filtration, then fractionated by a combination of anion-exchange, normal-phase, and high-pH anion-exchange liquid chromatography. The O-glycans, released from the Oglycoprotein by alkaline borohydride treatment, were fractionated by anion-exchange high-performance liquid chromatography (HPLC). The structures of individual components were analysed by 500 MHz 1 H NMR spectroscopy, in most cases combined with MALDI-TOF MS. In contrast to the structural data reported for native serum hC1INH, rhC1INH contained a broad array of different N-glycans, made up of oligomannose-, hybrid-, and complex-type structures. In the case of complex-type N-glycans (partially) (a2-6)-sialylated (N-acetylneuraminic acid only), mono-and diantennary chains were found; part of the diantennary structures were (a1-6)-core-fucosylated or (a1-3)-fucosylated in the lower or upper antenna (Lewis x). The manno-oligosaccharide pattern of part of the hybrid-and oligomannose-type structures indicates that besides the usual N-glycan processing route, also the alternative endo-mannosidase pathway is followed. The small core 1-type O-glycans showed the usual (a2-3)-and (a2-6)-sialylation pattern of O-glycoproteins of nonmucinous origin.
Introduction
Human C1 inhibitor (hC1INH), a plasma protease inhibitor belonging to the serine protease inhibitors superfamily synthesized in the liver, is involved in the inhibition of components of the complement, coagulation, fibrinolytic, and kinin-releasing systems (Carreer, 1992) . The singlechain polypeptide backbone of the plasma glycoprotein (M r~7 1 kDa) consists of 478 amino acids and has six N-glycosylation sites at respectively , and seven O-glycosylation sites at respectively (Bock et al., 1986; Perkins, 1993) . Its average carbohydrate content is about 26% (Perkins et al., 1990) . 1 H nuclear magnetic resonance (NMR) studies of chemically-released N-and Oglycans of native serum hC1INH revealed the presence of (a2-3)-disialylated and (a2-6)-disialylated complex-type diantennary N-glycans (molar ratio, 2:1), and the (a2-3)-monosialylated core 1-type O-glycan (Strecker et al., 1985) . The N-glycans were (a1-6)-core-fucosylated for 30%, and the only sialic acid found was N-acetylneuraminic acid. Profiling studies using high-voltage paper electrophoresis followed by size-exclusion chromatography of chemically released N-glycans indicated, besides the presence of major amounts of sialylated diantennary structures, also lower amounts of sialylated tri-and tetraantennary structures (Perkins et al., 1990) . Lectin-binding assays confirmed the presence of both (a2-3)-and (a2-6)-linked sialic acid and core 1-type O-glycans and favored the presence of complex-and hybrid-type N-glycans; no indications for oligomannose-type structures were obtained (Schoenberger, 1992) .
Deficiency in the gene encoding hC1INH causes a condition called hereditary angioneurotic edema, which can be lethal when left untreated (Ebo and Stevens, 2000; Carugati et al., 2001) . Furthermore, the lack of hC1INH leads to excessive complement activation, and this in turn to severe symptoms characterized by sudden local swellings of soft connective tissue (Ebo and Stevens, 2000) . Current forms of treatment include hC1INH replacement therapy, which relies on hC1INH supplies prepared from donated human blood. However, there is a growing number of clinical conditions wherein hC1INH might be beneficial (Caliezi et al., 2000) , hence current supplies of hC1INH are not likely to meet clinical demands.
Recombinant glycoprotein production in mammary glands of transgenic animals with milk extraction is one of the most attractive approaches for the economic and large-scale production of therapeutic glycoproteins (Houdebine, 1995; Colman, 1996) . In addition to providing eukaryotic posttranslational modifications often required for biological activity, it is also the expression platform that provides the highest recombinant protein production capacity available to date, exceeding the capacity of the more established mammalian cell lines. Typical examples so far are human lactoferrin in mice and cows (Van Berkel et al., 2002) , human a-glucosidase in mice (Bijvoet et al., 1996) and rabbits (Visser et al., 2000) , human granulocyte-macrophage colony stimulating factor in mice , human erythropoietin in mice and rabbits , human antithrombin in goats (Edmunds et al., 1998) , and human tissue-type plasminogen activator in goats (Denman et al., 1991) .
The posttranslational glycosylation of proteins is a species-, tissue-, cell-type-, and protein-specific phenomenon. Thus recombinant proteins can have different glycosylation patterns when compared with their native counterparts. Furthermore, in cell cultures, changes in growth media composition and in growth conditions may lead to changes in glycosylation patterns. These findings are of special interest when focusing on human therapeutic recombinant glycoproteins, because specific glycosylation patterns play important roles in the secretion, antigenicity, and clearance of glycoproteins (Jenkins and Curling, 1994; Jenkins et al., 1996; Kamerling, 1996; Varki et al., 1999; Galet et al., 2001) .
Nowadays, much knowledge is available with respect to the glycosylation machineries of the two most popular mammalian cell lines for glycoprotein expression, Chinese hamster ovary (CHO) and baby hamster kidney (BHK) cells (Kamerling, 1996) . However, detailed glycan data and systematic studies on the glycosylation capabilities of the mammary glands of the different species, including the effects of stage of lactation, individual variation, and seasonal variation, are scarce. For human lactoferrin from cow milk (Van Berkel et al., 2002) it was concluded that besides complextype N-glycans, as in natural human lactoferrin, also oligomannose-and/or hybrid-type glycans do occur, whereas the presence of N,N H -diacetyllactosediamine units has been suggested. It has been reported that natural bovine lactoferrin contains complex-(both partially [a2-6]-sialylated Nacetyllactosamine and N,N H -diacetyllactosediamine units, and Gal[a1-3]Gal[b1-4]GlcNAc units) and oligomannosetype N-glycans (Montreuil et al., 1997) . The occurrence of N,N H -diacetyllactosediamine units has also been suggested for human antithrombin produced in goat milk (Edmunds et al., 1998) . In the latter case, in contrast to plasma human antithrombin, the transgenic form also contained oligomannose-type structures, and in addition to N-acetylneuraminic acid, N-glycolylneuraminic acid was detected.
Because the glycosylation machinery of the rabbit mammary glands is rather unexplored, it is unpredictable what kind of glycans would predominate on recombinant glycoproteins from transgenic rabbit milk. In this study, a detailed analysis of the N-and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits (rhC1INH) is presented and discussed.
Results

General
Monosaccharide analysis of rhC1INH, having a total carbohydrate content of 14% (w/w), revealed the presence of Fuc, Gal, GalNAc, GlcNAc, Man, and Neu5Ac in the molar ratio 0.2:2.4:1.7:2.6:3.0:1.3.
Release and fractionation of N-glycans of rhC1INH
The N-glycans of rhC1INH were released by peptide-N 4 -(N-acetyl-b-glucosaminyl)asparagine amidase F (PNGase F) digestion, separated as a pool from the remaining O-glycoprotein, and fractionated by anion-exchange chromatography on Resource Q. Three carbohydratecontaining fast protein liquid chromatography (FPLC) fractions, eluting at positions corresponding to neutral N0 (25%), monosialylated N1 (67%), and disialylated N2 (8%) structures were obtained ( Figure 1 ). Neutral FPLC fraction N0 was further separated into six high-performance liquid chromatography (HPLC) fractions, denoted N0.1±N0.6, by normal phase chromatography on LiChrospher-NH 2 (Figure 2 ). The HPLC fractions N0.3 and N0.4 were subfractionated by high pH anion-exhange chromatography (HPAEC) on CarboPac PA-1 ( Figure 3 ) after 2-aminobenzamide (2AB) labeling of the components present (to minimize high pH±induced epimerization of the reducing GlcNAc residues during HPAEC; Stroop et al., 2000) , yielding four and five subfractions, respectively, denoted N0.3.1 2AB ±N0.3.4 2AB and N0.4.1 2AB ±N0.4.5 2AB . The mono-(N1) and dicharged (N2) FPLC fractions were subfractionated on CarboPac PA-1 (Figures 4 and 5) , yielding fractions N1.1±N1.8 and N2.1±N2.3, respectively.
Structural analysis of the various fractions was carried out by 1 H NMR spectroscopy in combination with (Ha Ê rd et al., 1992) . In case of hybrid-and oligomannose-type N-glycans, the N-acetyl methyl signals of GlcNAc-2 are generally observed at~d 2.064 (Stroop et al., 2000; Tseneklidou-Stoeter et al., 1995) . 
N-and O-glycans of rhC1INH
Structural analysis of neutral N-glycans The 1 H NMR data of the identified neutral oligomannose-, hybrid-, and complex-type N-glycans are presented in Table I . The table includes also the coding system for the different monosaccharide constitutents. In the HPAEC subfraction N0.3.1 2AB no carbohydrate material could be detected, whereas HPAEC subfractions N0.4.1 2AB and N0.4.3 2AB did not contain sufficient material for NMR assignments. The same held for HPLC fraction N0.6.
MALDI-TOF-MS analysis (positive-ion mode) of HPLC fraction N0.1 showed a sodiated molecular ion at m/z 1136 [Hex 3 HexNAc 3 Na]. Its 1 H NMR spectrum indicated a monoantennary N-glycan whereby Man-4 is 1 H-chemical shifts of the structural-reporter-group protons of the constituent monosaccharides of neutral N-glycans, derived from rhC1INH
Chemical shifts are given at 300K and were measured in 2 H 2 O at p 2 H7 relative to internal acetone (d 2.225; Vliegenthart et al., 1983) . Compounds are represented by short-hand symbolic notation: &, Fuc; &, Gal; *, GlcNAc;^, Man; 2AB, 2-aminobenzamide. For numbering of the monosaccharide residues, see Ã and ÃÃ. n.d., not determined; a and b stand for the anomeric configuration of GlcNAc-1.
extended with H is terminal. The structural-reporter-group protons of Man-3, Man-4, Man-4 H , and GlcNAc-5 match the 1 H NMR data of the (a1-6)-fucosylated analogue (compare with compound 5 in Bendiak et al. [1988] H on the a1-6 branch, whereas Man-4 on the a1-3 branch carries an N-acetyllactosamine unit.
1 H NMR data of a similar structure, but a(2-3)-sialylated and with GlcNAc-2 as reducing unit have been reported (compare with compound EH-1 in Spellman et al. [1991] Table I ). The assignments of the various Man H-1 and H-2 signals were verified by 2D total correlation spectroscopy (TOCSY) experiments. The structural assignment was further supported by 2D rotating-frame nuclear Overhauser enhancement spectroscopy (ROESY), showing cross-peaks between Man-D 2 H-1 and Man-A H-2 and between Man-4 H-1 and Man-3 H-3.
HPAEC subfraction N0.3.4 2AB turned out to contain a mixture of a hybrid-and an oligomannose-type N-glycan. with GlcNAc-5 (N0.3.4A 2AB ) and the second one for Man-4 substituted with Man-C (N0.3.4B 2AB ) (Vliegenthart et al., 1983) . Therefore the structural reporters clearly indicate two structures with the same upper arm and variations in the substitution of Man-4 in the lower arm (molar ratio A:B, 5:8). The downfield shifts of Man-4 H-1/H-2, caused by the attachment of GlcNAc-5, going from N0.2 2AB to N0.3.4A 2AB , is comparable with such shifts reported in the literature (Mulder et al., 1995) . Compound N0.3.4B 2AB is the conventional Man 6 GlcNAc 2 structure, and taking into account the influence of the 2AB labeling, the structural reporters are in agreement with those of the nonlabeled compound (Tseneklidou-Stoeter et al., 1995) . HPAEC subfraction N0.4.2 2AB contains a digalactosylated diantennary complex-type N-glycan. The 1 H NMR structural-reporter groups are in accordance with earlier published data for such a glycan (compare with compound 11 in Bendiak et al. [1988] ), except for the values affected by the 2AB labeling. Note the difference in d value between GlcNAc-2 NAc for complex-type (d 2.072) and hybrid-/oligomannose-type (d 2.055±2.062) 2-AB-labeled N-glycans (Table I) . .
MALDI-TOF-MS analysis
Structural analysis of monosialylated N-glycans
The 1 H NMR data of the identified monosialylated hybrid-and complex-type N-glycans are presented in Table II. The table includes 1 H-chemical shifts of the structural-reporter-group protons of the constituent monosaccharides of sialylated N-glycans, derived from rhC1INH
Chemical shifts are given at 300K and were measured in 2 H 2 O at p 2 H7 relative to internal acetone (d 2.225; Vliegenthart et al., 1983) . Compounds are represented by short-hand symbolic notation: *, Neu5Ac(a2-6); &, Fuc; &, Gal; *, GlcNAc;^, Man. For numbering of the monosaccharide residues, see Ã. n.d., not determined; a and b stand for the anomeric configuration of GlcNAc-1.
N-and O-glycans of rhC1INH
(slightly influenced by the type of upper arm) (compare with compound HST in Damm et al. [1987] ).
The 1 H NMR spectrum of HPAEC fraction N1.1 showed the presence of a diantennary N-glycan, (a2-6)-sialylated at the lower arm and an (a1-6)-fucosylated GlcNAc-1 residue. The upper arm contains a Lewis x epitope as indicated by the typical structural reporters of the monosaccharide constituents (compare with compound Qd1.6A in Stroop et al., 2000) . As indicated by 1 H NMR analysis, HPAEC fraction N1.2 contains the noncore-fucosylated analog of N1.1. The 1 H NMR spectrum of HPAEC fraction N1.3 reflects the presence of a convential (a1-6)-core-fucosylated diantennary N-glycan, (a2-6)-sialylated at the (a1-3) arm (compare with compound N1.5 in Ha Ê rd et al. [1992] ).
1 H NMR analysis of HPAEC fraction N1.4 showed the presence of a monoantennary N-glycan, (a2-6)-sialylated at the (a1-3) arm. (Figure 6 ). 1 H NMR analysis of the neutral FPLC fraction O.1 showed the presence of the core 1 structure Gal(b1-3)GalNAc-ol (compare with compound 2 in Kamerling and Vliegenthart [1992] ) (Table III) . The monocharged FPLC fraction O.2 contained a mixture of two monosialylated alditols, Neu5Ac(a2-3)Gal(b1-3)GalNAc-ol (O.2A) (compare with compound 78 in Kamerling and Vliegenthart [1992] ) and Gal(b1-3)[Neu5Ac(a2-6)]GalNAc-ol (O.2B) (compare with compound 9 in Kamerling and Vliegenthart [1992] [Neu5Ac(a2-6)]GalNAc-ol (compare with compound 85 in Kamerling and Vliegenthart [1992] ).
Discussion
In 1985 an 1 H NMR analysis of the carbohydrate chains of native hC1INH, purified from normal serum, was reported (Strecker et al., 1985) , and, following our coding system, compounds N2.1, N2.2, and O.2A, and the (a2-3)-disialylated isomers of N2.1 and N2.2 were shown to occur. In view of the followed isolation protocol it is tempting to assume that only major components were identified. Vliegenthart et al., 1983) . Compounds are represented by short-hand symbolic notation:~, Neu5Ac(a2-3); *, Neu5Ac(a2-6);^, GalNAc; &, Gal. n.d., not determined.
N-and O-glycans of rhC1INH
Additional profiling studies (Perkins et al., 1990) indicated that besides sialylated complex-type diantennary, also low amounts of tri-and tetraantennary N-glycans do occur. Lectin-based assays revealed the occurrence of (a2-6)/ (a2-3)-sialylated complex-and hybrid-type N-glycans (Schoenberger, 1992) . Recently, biologically active rhC1INH with mainly oligomannose-type N-glycans has been expressed in a baculovirus expression system (Wolff et al., 2001) .
Here, we focus on the N,O-glycosylation pattern of rhC1INH, the transgenic material expressed in the mammary gland of transgenic rabbits, excreted in the milk. A first inspection of the results learns that oligomannose-, hybrid-, and diantennary complex-type N-glycans do occur. When sialylated, only Neu5Ac is present, and only (a2-6) linkages are found. Part of the complex-type N-glycans contains the Lewis x epitope. The small core 1-type O-glycans show the usual (a2-3)-and (a2-6)-sialylation pattern of O-glycoproteins of nonmucinous origin. Neu5Gc, found in low amounts in CHO-and BHKexpressed recombinant glycoproteins (Hokke et al., 1990; Nimtz et al., 1993) and suggested to occur in transgenic human antithrombin produced in goat milk (Edmunds et al., 1998) , was not observed on the rhC1INH glycans. This sialic acid is not expressed in normal adult human cells; higher levels of Neu5Gc may lead to immune reactions in humans. In this context, it should be noted that N-glycans of CHO-and BHK-derived recombinant glycoproteins contain (a2-3)-linked sialic acid only. Another welldocumented immunogenic carbohydrate antigen, Gal(a1-3) Gal(b1-4)GlcNAc(b1- (Hamadeh et al., 1992) , was also not detected in rhC1INH.
In Table IV a survey is presented of the amounts in molar percentages of the N-and O-glycans established. The neutral N-glycans in rhC1INH make up about 25% of the total N-glycan pool. The majority of these glycans were of the oligomannose-and hybrid-type, with Man 5 GlcNAc 2 being the most abundant structure, accounting for about 10% of the total N-glycan pool. About 75% of the N-glycans were sialylated. The monocharged N-glycans (about 67% of the total N-glycan pool) were of the hybrid-and mono-or diantennary complex type. Here, the major structures were the monosialylated, partially (a1-6)-fucosylated diantennary N-glycans (about 30% of the total N-glycan pool). The dicharged N-glycans (about 8% of the total N-glycan pool) comprised disialylated, partially (a1-6)-fucosylated diantennary N-glycans. In this context it is of interest to mention that with increasing expression levels of rhC1INH, the ratio of oligomannose-type:hybrid-type N-glycans increases and that a decrease in the extent of sialylation occurs with the progress of lactation (Koles et al., unpublished data).
An evaluation of the N-glycosylation pattern found for rhC1INH indicates that several of the oligomannoseand hybrid-type glycans contained a Man-D 2 residue, which is rather unusual for mature glycoproteins. Following the major pathway in the trimming of glycoprotein Nglycans from Glc 3 Man 9 GlcNAc 2 to Man 5 GlcNAc 2 , the three Glc residues are removed by the endoplasmic reticulum (ER)±resident glucosidases I and II and Man-D 2 by a Golgi-localized a-mannosidase I, yielding a specific Man 8 GlcNAc 2 isomer. Two other alternate early processing Tables I±III). routes to Man 8 GlcNAc 2 isomers comprise the removal of Man-D 2 by ER-localized a-mannosidase I or of Man-D 3 by ER-localized a-mannosidase II. In the Golgi (or partially in the ER), specific a-mannosidases release the remaining Man-D residues and Man-C Spiro, 1993, 1996; Verbert, 1995) .
The finding of Man 8 GlcNAc 2 isomer N0.4.5, containing Man-D 2 and Man-D 3 indicate that in the mammary gland of the rabbit the alternative endo-mannosidase pathway (More and Spiro, 1990) is competetively active. Here a Glc(a1-3)Man disaccharide is released by a Golgi-localized endo-a-mannosidase yielding Man 8 GlcNAc 2 missing Man-D 1 , followed by a sequential cleavage of Man-D 3 and Man-C by Golgi-localized a-mannosidases (Verbert, 1995) , yielding the Man 6 GlcNAc 2 isomer N0.3.3, the second most abundant oligomannose-type structure in this study (a product that also could arise from the ER-a-mannosidase II processing). Interestingly, the endo-mannosidase pathway seems to be an active pathway in the mammary glands of cow, goat, sheep, and rhesus monkey, too, as lactoferrins from these animals contain, in addition to Man 9 GlcNAc 2 , the Man 8 GlcNAc 2 structure N0.4.5 (Van Halbeek et al., 1981; Coddeville et al., 1992; Montreuil et al., 1997) . Usually the endo-mannosidase pathway, a processing with one exception so far only observed in vertebrates (Dairaku and Spiro, 1997) , is followed for circumventing a-glucosidase blockades (Moore and Spiro, 1990; De Praeter et al., 2000) but can also be induced by inhibiting ER/Golgi-localized a-mannosidases I, thereby blocking the formation of Man 8 GlcNAc 2 missing Man-D 2 (Weng and Spiro, 1996) . The reason why the mammary tissue is using partly the endo-mannosidase pathway remains to be clarified.
Comparing the N-glycosylation patterns of native serum hC1INH and rhC1INH (Table IV) , it can be concluded that the total processing in native serum hC1INH (only N2.1/ N2.2 and the [a2-3]-sialylated isomers) is much more complete than in rhC1INH (N2.1/N2.2 make up about 10% of the total N-glycan pool). Comparing the O-glycosylation patterns of native serum hC1INH and rhC1INH (Table IV) , it is remarkable that the only structure (O.2A) present in native material is a minor one (about 10% of the total O-glycan pool) in the recombinant material. In rhC1-INH the (a2-6)-sialylated extensions of O.1 and O.2A are the major products (about 60% of the total O-glycan pool). Taking together, when compared with native serum hC1-INH, in terms of sialylation the N-glycans of rhC1INH are (a2-6)-undersialylated [Gal(b1-4)GlcNAc a-2,6-sialyltransferase/ST6Gal I], whereas the O-glycans are (a2-6)-oversialylated (GalNAc a-2,6-sialyltransferase/ST6GalNAc II].
Biological activity studies of rhC1INH are in progress and will be published elsewhere.
The detailed analysis of the N,O-glycosylation pattern of rhC1INH, revealing remarkable differences in glycosylation pattern between native serum hC1INH and rhC1INH, makes clear the importance of such studies for therapeutic glycoproteins when expressed in new biological systems. Earlier research has demonstrated the usefulness of studying the glycosylation machinery of CHO and BHK cells, and similar research has to be set up to explore the glycosylation machinery of the mammary gland of animals used for transgenic purposes.
Materials and methods
Release and isolation of N-glycans Purified rhC1INH, isolated from pooled milk of line 2972p, was obtained from Pharming Technologies BV (Leiden, Netherlands). The N-glycans of rhC1INH were enzymically released with PNGase F (EC 3.5.1.52) (Roche Molecular Biochemicals, Indianapolis, IN), using incubation conditions optimized for rhC1INH. Briefly, 100 mg rhC1INH, dissolved in 5 ml 20 mM PBS pH 7.2 (Fluka, Buchs, Switzerland) containing 10 mM ethylenediamine tetraacetic acid, was denatured in the presence of 10% sodium dodecyl sulfate (w/v) and 10 mM 2-mercaptoethanol for 5 min at 100 C, then digested with 5 U/mg PNGase F in the presence of 6.4 mg/ml 3-[(3-cholamidodopropyl)dimethylammonio]-1-propanesulfonate (Fluka) for 24 h at 37 C. Portions of the digest were filtered through 30 kDa cut-off centrifugal concentrators and the filtrates, containing the released N-glycans, desalted on graphitized carbon columns (Alltech, Breda, the Netherlands) (Packer et al., 1998) after removal of detergents by Calbiosorb (Calbiochem, San Diego, CA) beads. The concentrated N-deglycosylated glycoprotein (~0.4 ml) was then extensively dialyzed and subjected to de-O-glycosylation.
Release and isolation of O-glycans N-deglycosylated rhC1INH was subjected to alkaline borohydride treatment according to Piller and Piller (1993) . Briefly, the concentrated N-deglycosylated glycoprotein solution (~0.4 ml) was mixed with 10 ml 0.1 M NaOH containing 1 M NaBH 4 , and kept for 16 h at 45 C, then cooled on ice and neutralized with 2 M aqueous HOAc. Boric acid was removed by repetitive coevaporation with MeOH, containing 1% (v/v) HOAc. Finally, the material was applied to a Dowex 50W-X8, H column (100±200 mesh, Pharmacia), and O-glycans (oligosaccharide-alditols) were eluted with water and lyophilized. When required, samples were further purified on graphitized carbon columns (Packer et al., 1998) .
FPLC fractionation
The pools of N-and O-glycans were fractionated into neutral and charged species on a Resource Q column (6 ml, Pharmacia, Uppsala, Sweden) using a Pharmacia FPLC system. Elutions were performed with water followed by a linear concentration gradient of NaCl in water at a N-and O-glycans of rhC1INH flow rate of 4 ml/min; for gradient details, see relevant figure captions. Fractionations were monitored by UV absorbance at 214 nm and conductivity measurements. Individual fractions were lyophilized, desalted on 5 connected HiTrap columns (5 ml, Amersham, Little Chalfont, U.K.) using 5 mM NH 4 HCO 3 as eluent, and lyophilized again.
HPLC fractionation
The FPLC fraction of neutral N-glycans was further fractionated on a LiChrospher-NH 2 5 mm (250 mm Â 4.6 mm, Alltech) column equipped with a LiChrospher Amino 5 mm guard column (7.5 Â 4.6 mm), using a Waters 600 HPLC system. Elutions were carried out with a linear gradient of water in acetonitrile at a flow rate of 1 ml/min; for gradient details, see relevant figure captions. The fractionation was monitored by UV absorbance at 206 nm. Individual fractions were lyophilized.
Labeling of N-glycans with 2AB
Neutral N-glycans from the HPLC fractionation were treated with 0.35 M 2AB (Sigma)/1 M NaCNBH 3 in Me 2 SO±HOAc (7:3, v/v) for 2 h at 65 C (Bigge et al., 1995; Stroop et al., 2000) . The 2AB fluorescently labeled glycans were purified via paper chromatography on acidpretreated QMA (Whatman) filter paper strips using acetonitrile (three times) as a mobile phase. Glycans (remaining at the base line) were eluted from the dried paper strips with water, concentrated, and subfractionated by HPAEC.
HPAEC fractionation
HPAEC was performed on a Dionex DX 500 workstation equipped with a pulsed amperometric detection (PAD) system. A series of N-glycan fractions were subfractionated on a CarboPac PA-1 (250 Â 9 mm) column using linear gradients of 0.5 M NaOAc in 0.1 M NaOH at a flow rate of 4 ml/min; for gradient details, see relevant figure captions. The following pulse potentials and durations were used during the triple-pulse amperometric detection with a gold electrode at 300 mA: E 1 0.05 V, 480 ms; E 2 0.60 V, 120 ms; E 3 À0.60 V, 60 ms. Fractions were immediately neutralized with 0.1 M HCl, then lyophilized, desalted on five connected HiTrap columns (5 ml, Amersham Pharmacia) using 5 mM NH 4 HCO 3 as eluent, and lyophilized again.
Quantification of oligosaccharides
The molar ratio of the FPLC fractions was calculated from the FPLC peak areas on the basis of the weighted average number of CO groups (responsible for UV absorption at 214 nm) being known after structural identification and determination of the relative amounts of each individual component. The molar ratio of the constituent oligosaccharides within each FPLC fraction was determined from the HPLC peak areas (corrected for the number of CO groups) at 206 nm. When HPAEC/PAD was used for further fractionation of HPLC fractions, the PAD response was assumed to be equal for each oligosaccharide present within one HPLC fraction. For mixtures, molar ratios were determined on the basis of the 1 H NMR spectra. 1 H NMR spectra were recorded at 500 MHz on a Bruker AMX-500 spectrometer (Bijvoet Center, Department of NMR Spectroscopy, Utrecht University) at a probe temperature of 300K and p 2 H 7. 1D spectra of 5000 Hz spectral width were recorded in 16K complex data sets using a water eliminated Fourier transform pulse sequence as described by Ha Ê rd et al. (1992) (Vliegenthart et al., 1983) . 2D-TOCSY spectra at 500 MHz were recorded using Bruker software with MLEV-17 mixing sequence cycles between 20 and 100 ms. Data matrices of 512 Â 2048 points were collected, representing a spectral width of 4800 Hz in each dimension. The 2 HO 1 H signal was suppressed by presaturation for 1 s during the relaxation delay. 2D-ROESY spectra were recorded with a mixing time of 300 ms. Phase-sensitive handling of data was performed by the time-proportional phase increment method implemented by the Bruker software. NMR data were processed using a locally developed software package (J. A. van Kuik, Bijvoet Center, Department of Bio-Organic Chemistry, Utrecht University).
MS
For MALDI-TOF-MS in the positive-ion mode, samples (0.5±1 ml) were mixed in a 1:1 ratio with a mixture of 5 mg/ml 2,5-dihydroxybenzoic acid and 0.25 mg/ml 5-methoxysalicylic acid in 1 ml ethanol/10 mM NaCl (1:1, v/v) as a matrix. For the negative-ion mode, 2 mg/ml 2 H ,4 H , 6
H -trihydroxyacetophenone monohydrate in acetonitrile/13.3 mM ammonium citrate (1:3, v/v) was used as a matrix. In this case the sample matrix mixture was dried under reduced pressure (Papac et al., 1998) . Measurements were performed on a PerSeptive Biosystems Voyager-DE MALDI-TOF mass spectrometer with implemented delayed extraction technique using an N 2 laser (337 nm) with 3 ns pulse width. Spectra were recorded in a linear mode at an accelerating voltage of 24.5 kV using an extraction delay of 90 ns.
NMR, nuclear magnetic resonance; PAD, pulsed amperometric detection; PNGase F, peptide-N 4 -(N-acetylb-glucosaminyl)asparagine amidase F; rhC1INH, recombinant-rabbit human C1 inhibitor; ROESY, rotatingframe nuclear Overhauser enhancement spectroscopy; TOCSY, total correlation spectroscopy.
